Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.

Linazasoro G.

Arch Neurol. 2007 Jan;64(1):137-40. Review. No abstract available.

PMID:
17210824
2.

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.

Bezard E, Brotchie JM, Gross CE.

Nat Rev Neurosci. 2001 Aug;2(8):577-88. Review.

PMID:
11484001
3.

New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.

Hadj Tahar A, Grondin R, Grégoire L, Calon F, Di Paolo T, Bédard PJ.

Adv Neurol. 2003;91:51-64. Review. No abstract available.

PMID:
12442663
4.

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

Fox SH, Chuang R, Brotchie JM.

Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Review.

PMID:
18772047
5.

Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.

Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A.

Prog Brain Res. 2008;172:465-78. doi: 10.1016/S0079-6123(08)00922-9. Review.

PMID:
18772046
6.

Therapeutic strategies to prevent motor complications in Parkinson's disease.

Kieburtz K.

J Neurol. 2008 Aug;255 Suppl 4:42-5. doi: 10.1007/s00415-008-4007-4. Review.

PMID:
18821085
7.

Mechanisms of motor complications in treatment of Parkinson's disease.

Kumar A, Huang Z, de la Fuente-Fernández R.

Adv Neurol. 2003;91:193-201. Review. No abstract available.

PMID:
12442678
8.

Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity.

Linazasoro G.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):22-7. doi: 10.1097/WNF.0B013E3181634EA6.

PMID:
18978500
9.

Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.

Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.

Brain. 2009 Feb;132(Pt 2):319-35. doi: 10.1093/brain/awn305.

PMID:
19039008
11.

Parkinson's disease: levodopa-induced dyskinesia and signal transduction.

Santini E, Valjent E, Fisone G.

FEBS J. 2008 Apr;275(7):1392-9. doi: 10.1111/j.1742-4658.2008.06296.x. Review.

12.

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.

Picconi B, Paillé V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela Cenci M, Calabresi P.

Neurobiol Dis. 2008 Feb;29(2):327-35.

PMID:
17997101
13.

[An implication of serotonergic fibers which goes beyond Levodopa-induced dyskinesia].

Beaudoin-Gobert M, Tremblay L, Sgambato-Faure V.

Med Sci (Paris). 2015 Nov;31(11):956-9. doi: 10.1051/medsci/20153111006. French. No abstract available.

14.
15.

Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.

Carlsson T, Carta M, Winkler C, Björklund A, Kirik D.

J Neurosci. 2007 Jul 25;27(30):8011-22.

16.

Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.

Stacy M, Galbreath A.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):51-6. doi: 10.1097/WNF.0b013e318065b088. Review.

PMID:
18303491
17.

Levodopa in the early treatment of Parkinson's disease.

Murata M.

Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S17-20. doi: 10.1016/S1353-8020(09)70006-9. Review.

PMID:
19131036
18.

Dopamine receptors and locomotor responses: molecular aspects.

Sealfon SC.

Ann Neurol. 2000 Apr;47(4 Suppl 1):S12-9; discussion S19-21. Review.

PMID:
10762128
19.

Levodopa addiction in idiopathic Parkinson disease.

Borek LL, Friedman JH.

Neurology. 2005 Nov 8;65(9):1508. No abstract available.

PMID:
16275855
20.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235.

PMID:
18952677

Supplemental Content

Support Center